The DOI matches its Crossref record.
Aminoglycoside Toxicity in the Treatment of Endophthalmitis
Abstract
OBJECTIVE AND METHODS: Intravitreous aminoglycosides are widely used for the treatment and prophylaxis of endophthalmitis. Because the toxicity of 0.4 mg of gentamicin sulfate is well documented, many surgeons now use amikacin sulfate or low-dose gentamicin to reduce the risk of macular infarction. A survey of retinal specialists has suggested that amikacin or low-dose gentamicin can also cause macular toxic side effects. To further investigate this issue, the critical details of the case histories, findings, and course of 13 patients who received intravitreous injections of 0.2 to 0.4 mg of amikacin sulfate or 0.1 to 0.2 mg of gentamicin sulfate for prophylaxis or treatment of endophthalmitis are summarized. For several patients, complete case histories and a fluorescein angiogram are provided. RESULTS: These cases suggest that amikacin and low-dose gentamicin, similar to gentamicin sulfate at a dose of 0.4 mg, can cause macular infarction. The causative dose cannot be ascertained in any of the cases, but doses were prepared by hospital pharmacists using typewritten protocols, a practice that helps to prevent dilution errors. Several of these cases differ from previously reported cases of aminoglycoside toxicity in that the involvement of the macula was quite discrete. Most of the patients suffered severe visual loss, but two patients, in whom most of the nonperfusion was adjacent to the macula and in whom some of the perifoveal capillaries were spared, recovered 20/50 visual acuity. CONCLUSIONS: These cases emphasize the potential hazards of the intravitreous use of aminoglycosides. A toxic reaction can occur even when injection of low doses is intended and precautions are made to avoid dilution errors. A localized increase in concentration in dependent areas of the retina may play a role in aminoglycoside toxicity. If some of the perifoveal capillaries are spared, retention of some central vision is possible. Consideration should be given to substituting ceftazidime for aminoglycosides for the treatment and prophylaxis of endophthalmitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Spectrum and Susceptibilities of Microbiologic Isolates in the Endophthalmitis Vitrectomy Study
HAN, D. P., WISNIEWSKI, S. R., WILSON, L. A., BARZA, M., VINE, A. K., DOFT, B. H., KELSEY, S. F., & THE ENDOPHTHALMITIS VITRECTOMY STUDY GROUP (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)71959-2 · Cited by 702
Endogenous bacterial endophthalmitis: A 17-year prospective series and review of 267 reported cases
Jackson, T. L., Eykyn, S. J., Graham, E. M., & Stanford, M. R. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00054-7 · Cited by 549
Bacterial Endophthalmitis: Epidemiology, Therapeutics, and Bacterium-Host Interactions
Callegan, M. C., Engelbert, M., Parke, D. W., Jett, B. D., & Gilmore, M. S. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.1.111-124.2002 · Cited by 385
Varela-Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García-Otero, X., Luzardo-Álvarez, A., Fernández-Ferreiro, A., & Otero-Espinar, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030269 · Cited by 354
Kresloff, M. S., Castellarin, A. A., & Zarbin, M. A. (1998) · Survey of Ophthalmology · doi:10.1016/s0039-6257(98)00036-8 · Cited by 289
Metadata
- Authors
- Campochiaro, P. A.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 1994-01-01
- Volume
- 112
- Issue
- 1
- Pages
- 48
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W2170552482
- Cited by
- 199
- References
- 0
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aminoglycoside Toxicity in the Treatment of Endophthalmitis. https://app.cochat.ai/papers/10.1001/archopht.1994.01090130058017
- The paper
- Campochiaro, P. A. (1994). Aminoglycoside Toxicity in the Treatment of Endophthalmitis. Archives of Ophthalmology. https://doi.org/10.1001/archopht.1994.01090130058017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.